Advisory Board

Dr. William CS Cho

William CS Cho, Ph.D., RCMP, FHKIMLS, FHKSMDS, Chartered Scientist, FIBMS is Biomedical Scientist in the Department of Clinical Oncology at Queen Elizabeth Hospital, Hong Kong.

He is a Chartered Scientist granted by the Science Council (UK), a Registered Chinese Medicine Practitioner (HK), Guest Professor of a number of universities, and a Fellow Member of several institutes, including the Institute of Biomedical Science (UK), the Hong Kong Institute of Biomedical Science, and the Hong Kong Society for Molecular Diagnostic Sciences.

His main research interests have been focusing on cancer studies utilizing high-throughput technologies to discover biomarkers for cancer diagnosis, treatment prediction, and prognostication.

William has published over 600 peer-reviewed papers in journals such as Lancet, Lancet Oncology, Advanced Science, Nature Communications, Cancer Communications, PNAS, Science Advances, Journal of the National Cancer Institute, Journal of Extracellular Vesicles, Molecular Cancer, Theranostics, Clinical Cancer Research, Clinical Chemistry, and Annuals of Oncology.

These papers covered a wide range of topics including cancer biomarkers, non-coding RNAs, extracellular vesicles, drug repurposing, and Chinese medicine. William’s published papers have garnered more than 25,000 citations and he is listed in the top 2% most influential scientists in the world.

Additionally, William is the Editor of over two dozen books, including MicroRNAs in Cancer Translational Research, An Omics Perspective on Cancer Research, Supportive Cancer Care with Chinese Medicine, Drug Repurposing in Cancer Therapy: Approaches and Applications, and Resistance to Anti-CD20 Antibodies and Approaches for Their Reversal to name a few.

He is primarily focused on cancer studies with the aim of identifying biomarkers for cancer diagnosis, treatment prediction, and prognosis. As a seasoned researcher, he has employed various disciplines including molecular biology, proteomics, genomics, immunology, and bioinformatics to conduct cancer research.

William is also an internationally renowned grant reviewer of the Hope Funds for Cancer Research (USA), Cancer Research (UK), MRC Research Grant (UK), Health Research Board (Ireland), Science Foundation (Ireland), Istituto Toscano Tumori (Firenze), The Foundation Fournier-Majoie for Innovation (Brussels), National Medical Research Council (Singapore), The Medical Research Council (South Africa), and Academia Sinica Investigator Award (Taiwan).

Read Proteomics and translational medicine: molecular biomarkers for cancer diagnosis, prognosis and prediction of therapy outcome and Complementary and Alternative Medicine for Diabetes.

Read his Conquering cancer through discovery research, Targeted next-generation sequencing reveals recurrence-associated genomic alterations in early-stage non-small cell lung cancer, and Turning point for cancer management.

Read Performance comparison of the Cobas® Liat® and Cepheid® GeneXpert® systems on SARS-CoV-2 detection in nasopharyngeal swab and posterior oropharyngeal saliva and Association Between SNPs in the One-Carbon Metabolism Pathway and the Risk of Female Breast Cancer in a Chinese Population.

Follow him on ORCiD.